The SIRIC of Lyon is named LYric (Lyon Research Innovation for Cancer) and its scientific activities started in 2012 under the auspices of INCa.
LYric structures and organizes in hospital centers of excellence (Centre Léon Bérard – Regional Cancer Centre and Hospices Civils de Lyon – University Hospital) the efforts of basic and transfer researchers, and clinicians of Lyon struggling against cancer for a better care and follow-up of patients.
Researchers and clinicians work together in order to make a better use of present drugs and technologies, to give access to new treatment to patients, as well as better understand the tumor growth process and the reactivation of the immune system.
The selection of research themes have been naturally made thanks to the synergic work that has been set up. 3 programs have been identified: 1) inside the tumor cell, 2) the immune environment of the tumor, 3) the treatment of macroscopic tumor.
The programs benefit from the development and structuration of technological platforms in research and diagnosis labs, as well as innovative clinical research, but also education and communication programs with patients and health professionals.
The scientific programs rely on the research axis of CRCL (Cancer Center of Lyon) labellized by CNRS (CNRS 5286), l’Inserm (U 1052) and University Claude Bernard Lyon 1, and the others partners of LYric (IARC, INRIA and Synergie Lyon Cancer Foundation),. They aim to transfer to patients the research innovations developed on these sites.
The research programs analyze the genetic, immune and clinical complexity of neoplastic disease for the patients of Centre Léon Bérard and the Hospices Civils de Lyon.
This is a two-way street process: Research serve the patient for understanding, and develop diagnosis and innovative therapeutic solutions for them.
LYric structures and organizes works of researchers and clinicians for a multidisciplinary healthcare and follow-up of patients.
It has an duty of excellence and innovation. Its research programs have to propose new paradigms for oncology. They have to serve the patients.
The 5-years-funding of LYric are necessary, but will not be enough, to fully develop the research programs. The LYric teams will have to be innovative to propose solution for sustainable development of this network of excellence.